Krebs Jeremy D, Parry-Strong Amber, Braakhuis Andrea, Worthington Anna, Merry Troy L, Gearry Richard B, Foster Meika, Weatherall Mark, Davies Cheryl, Mullaney Jane, Ross Cecilia, Conroy Denise, Rolleston Anna, Lithander Fiona E
Department of Medicine, University of Otago, Wellington, Wellington, New Zealand.
Centre for Endocrine, Diabetes and Diabetes Research, Te Whatu Ora New Zealand Capital, Coast and Hutt Valley, Wellington, New Zealand.
Diabetes Obes Metab. 2025 Jan;27(1):368-376. doi: 10.1111/dom.16030. Epub 2024 Oct 29.
To test if a New Zealand food-based Mediterranean diet (NZMedDiet) with behavioural intervention improves cardiometabolic health and wellbeing.
A randomised controlled trial comparing 12 weeks of the NZMedDiet to usual diet in participants with increased cardiometabolic risk (metabolic syndrome severity score [MetSSS] > 0.35). The intervention group was provided with food and recipes to meet 75% of their energy requirements, supported by a behavioural intervention to improve adherence. The primary outcome measure was (MetSSS) after 12 weeks.
Two hundred individuals with mean (SD) age 49.9 (10.9) years of which 62% women were enrolled with their household/whānau. After 12 weeks, the mean (SD) MetSSS was 1.0 (0.7) in the control (n = 98) and 0.8 (0.5) in the intervention (n = 102) group; estimated difference (95% confidence interval [CI]) of -0.05 (-0.16 to 0.06), p = 0.35. The Mediterranean diet score (PyrMDS) was greater in the intervention group 1.6 (1.1-2.1), p < 0.001, consistent with a change to a more Mediterranean dietary pattern. Weight reduced in the NZMedDiet group compared with control (-1.9 kg [-2.0 to -0.34]), p = 0.006 and wellbeing, assessed by the SF-36 quality of life questionnaire, and improved across all domains. For example, the physical component summary score difference (95% CI) was 4.0 (2.4-5.7), p < 0.001, and the mental component summary score difference was 3.0 (0.7-5.2), p = 0.01.
In participants with increased cardiometabolic risk, food provision with a Mediterranean dietary pattern and a behavioural intervention did not improve metabolic risk scores but was associated with reduced weight and improved quality of life.
测试采用行为干预的新西兰基于食物的地中海饮食（NZMedDiet）是否能改善心脏代谢健康和幸福感。
一项随机对照试验，将12周的NZMedDiet与心脏代谢风险增加（代谢综合征严重程度评分[MetSSS]＞0.35）的参与者的常规饮食进行比较。干预组提供满足其75%能量需求的食物和食谱，并辅以行为干预以提高依从性。主要结局指标是12周后的（MetSSS）。
200名平均（标准差）年龄为49.9（10.9）岁的个体，其中62%为女性，与其家庭/毛利大家庭一起参与研究。12周后，对照组（n = 98）的平均（标准差）MetSSS为1.0（0.7），干预组（n = 102）为0.8（0.5）；估计差异（95%置信区间[CI]）为-0.05（-0.16至0.06），p = 0.35。干预组的地中海饮食评分（PyrMDS）更高，为1.6（1.1 - 2.1），p < 0.001，这与转变为更地中海式的饮食模式一致。与对照组相比，NZMedDiet组体重减轻（-1.9 kg [-2.0至-0.34]），p = 0.006，并且通过SF - 36生活质量问卷评估的幸福感在所有领域均有所改善。例如，身体成分总结评分差异（95% CI）为4.0（2.4 - 5.7），p < 0.001，心理成分总结评分差异为3.0（0.7 - 5.2），p = 0.01。
在心脏代谢风险增加的参与者中，提供地中海饮食模式的食物和行为干预并未改善代谢风险评分，但与体重减轻和生活质量改善相关。
